KMTS director sells 15,000 shares in planned trade

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares.

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares. The sale was executed at a weighted average price of $20.8095 per share, with individual trade prices ranging from $20.5400 to $21.3900.

After this transaction, Webster directly holds 395,467 common shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($312K)

Type	Security	Shares	Price	Value
Sale	Common Shares	15,000	$20.8095	$312K

Holdings After Transaction: Common Shares — 395,467 shares (Direct)

Footnotes (2)

1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.5400 to $21.3900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold: 15,000 shares Weighted average sale price: $20.8095 per share Post-transaction holdings: 395,467 shares +3 more

6 metrics

Shares sold 15,000 shares Open-market sale of common shares

Weighted average sale price $20.8095 per share Price for sold common shares

Post-transaction holdings 395,467 shares Direct KMTS common shares held after sale

Sale price range low $20.5400 per share Lowest price in sale range

Sale price range high $21.3900 per share Highest price in sale range

10b5-1 plan adoption date September 29, 2025 Date pre-arranged trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KMTS director Brian Daniel Webster report?

Brian Daniel Webster reported selling 15,000 KMTS common shares in an open-market transaction. The sale was disclosed on a Form 4 and reflects a planned disposition of a portion of his holdings under a trading plan.

At what price did Brian Daniel Webster sell KMTS shares?

The weighted average sale price was $20.8095 per KMTS share. Individual trades occurred at prices ranging from $20.5400 to $21.3900, according to the Form 4 footnote describing the transaction pricing details.

How many KMTS shares does Brian Daniel Webster hold after the sale?

After selling 15,000 shares, Brian Daniel Webster directly holds 395,467 KMTS common shares. This remaining stake, reported in the Form 4, shows that the transaction involved only a portion of his total direct ownership.

Was the KMTS insider sale by Brian Daniel Webster under a Rule 10b5-1 plan?

Yes, the transaction occurred under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans pre-schedule trades, indicating the timing of this insider sale was determined in advance rather than made opportunistically.

What does the weighted average sale price mean in the KMTS Form 4 filing?

The weighted average price of $20.8095 reflects multiple trades executed within a price range. For this KMTS sale, the filing notes individual transactions occurred between $20.5400 and $21.3900, with details by price level available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/15/2026	06/15/2026	S(1)		15,000	D	$20.8095(2)	395,467	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.5400 to $21.3900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)